ipamorelin igf-1 human study cjc-1295 trials gh increase Activation of the GH/IGF- 1 axis cjc-1295 ipamorelin increase gh igf-1

As used herein, the phrase active ingredient generally refers either to an originator construct or benchmark construct with a payload region or cargo or payload as described herein

PMID: 41490200 | doi:10.5435/JAAOSGlobal-D-25-00236

PeRx offers Tesamorelin, CJC-1295/Ipamorelin, and the Tesamorelin/Ipamorelin combination

Peptide Vials (CJC-1295 NO DAC + Ipamorelin, 10 mg blend each): 8 weeks 3 vials 12 weeks 4 vials 16 weeks 5 vials Insulin Syringes (U-100, 30- or 50-unit preferred for low volumes): Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution